Redmile Group, LLC Clovis Oncology, Inc. Transaction History

Redmile Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $566,069 - $964,009	-99,485 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $375,058 - $1.09 Million	99,485 New	99,485 $633,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $10.8 Million - $59.3 Million	-3,607,800 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $571,815 - $2.23 Million	145,500 Added 4.2%	3,607,800 $14.2 Million
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $14.1 Million - $28.3 Million	-1,101,629 Reduced 24.14%	3,462,300 $51.5 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $8.89 Million - $15.2 Million	503,400 Added 12.4%	4,563,929 $113 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $26.5 Million - $74.6 Million	2,282,229 Added 128.34%	4,060,529 $72.9 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $578,589 - $974,755	19,700 Added 1.12%	1,778,300 $52.2 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $18.4 Million - $27.4 Million	438,573 Added 33.22%	1,758,600 $80 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $18.7 Million - $27.4 Million	323,417 Added 32.45%	1,320,027 $89.8 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $66.9 Million - $84.5 Million	996,610	996,610 $82.1 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.